ActivBiotics going into liquidation after trial failure

ActivBiotics is calling it quits following the failure of its lead therapy. All its assets--which includes a library of 250 small molecules and 800 antibacterial compounds--are going on the auction block this week, with final bids due February 1. The company's lead drug, rifalazil, failed in trials as a new therapy for peripheral arterial disease. And last year the company dumped its plans to go public, citing market conditions. ActivBiotics was founded 11 years ago as Merlin Technologies.

- see the release for more
- read the report from MassHighTech

Related Article:
ActivBiotics, Metaphore sign merger agreement. Report

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.